Gilead Plans to Lift Restrictions on Cayston™ Supply in Early September

July 17, 2012

Gilead Sciences Inc. announced today that it plans to lift restrictions on the supply of its inhaled antibiotic Cayston™ on Sept. 4, 2012. The availability of Cayston in the U.S. has been limited since earlier this year.  

Until the supply restrictions are lifted, the drug will be available to people with CF who have chronic Pseudomonas aeruginosa infections and are currently using the drug regularly. People who have a significant medical need for Cayston and no adequate treatment alternative may be considered for an exception through a separate medical process up to Aug. 31.

Gilead said that once the supply restrictions are lifted, Cayston will be available by prescription through specialty pharmacies as it was before the shortage.

The CF Foundation will keep the CF community updated as information becomes available.

People with CF and their families who have questions about Cayston should speak with their CF doctor.

For more information about the availability of Cayston, call the Cayston Access Program at 1-877-722-9786 (1-877-7CAYSTON) between 8 a.m. – 8 p.m. (Eastern time), visit or email